"Chemotherapy, Adjuvant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
| Descriptor ID |
D017024
|
| MeSH Number(s) |
E02.186.170 E02.319.170
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Chemotherapy, Adjuvant".
Below are MeSH descriptors whose meaning is more specific than "Chemotherapy, Adjuvant".
This graph shows the total number of publications written about "Chemotherapy, Adjuvant" by people in this website by year, and whether "Chemotherapy, Adjuvant" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 2 | 2 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 3 | 3 |
| 2005 | 0 | 3 | 3 |
| 2006 | 0 | 4 | 4 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 3 | 3 |
| 2009 | 0 | 3 | 3 |
| 2010 | 1 | 7 | 8 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 3 | 3 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 4 | 4 |
| 2018 | 0 | 2 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 3 | 4 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemotherapy, Adjuvant" by people in Profiles.
-
Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial. Am J Clin Oncol. 2020 03; 43(3):173-179.
-
National Treatment Practice for Adrenocortical Carcinoma: Have They Changed and Have We Made Any Progress? J Clin Endocrinol Metab. 2019 12 01; 104(12):5948-5956.
-
Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx? for Hormone Receptor Positive Patients Undergoing Neoadjuvant Chemotherapy. Ann Surg Oncol. 2019 Oct; 26(10):3232-3239.
-
Temporal trends in management and outcomes of testicular cancer: A population-based study. Cancer. 2018 07 01; 124(13):2724-2732.
-
Predicting Survival and Response to Treatment in Gastroesophageal Neuroendocrine Tumors: An Analysis of the National Cancer Database. Ann Surg Oncol. 2018 May; 25(5):1418-1424.
-
Anaplastic astrocytoma: prognostic factors and survival in 4807 patients with emphasis on receipt and impact of adjuvant therapy. J Neurooncol. 2016 09; 129(3):557-565.
-
Utilization and impact of adjuvant therapy in anaplastic oligodendroglioma: an analysis on 1692 patients. J Neurooncol. 2016 09; 129(3):567-575.
-
Evolving concepts regarding the use of radiotherapy in the adjuvant management of periampullary pancreatic adenocarcinoma. Cancer J. 2012 Nov-Dec; 18(6):624-32.
-
Adjuvant endocrine therapy for breast cancer. Oncology (Williston Park). 2012 Jun; 26(6):541-7, 550, 552 passim.
-
Radiotherapy in the adjuvant management of pancreatic adenocarcinoma: is it helpful? Expert Rev Gastroenterol Hepatol. 2012 Apr; 6(2):149-61.